Eleven Biotherapeutics designs and develops novel therapeutics for ocular diseases using its AMP-Rx™ protein engineering platform.
We create a new breed of potent and selective ophthalmic proteins. Eleven is creating a pipeline of engineered protein drugs for ocular diseases that are rationally designed for improved biological and drug-like properties.
Our differentiated ophthalmic protein products are designed for therapeutic impact in the ocular space. Eleven has a proprietary pipeline of product candidates for the treatment of ocular disease. Our products are engineered to treat both front-of-the-eye and back-of-the-eye diseases in new and effective ways.
Our technology enables innovative protein therapeutics. Eleven's proprietary protein engineering technology opens the potential to modulate key molecular targets responsible for the initiation or maintenance of an ocular disease.
EBI-005, Eleven's lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in clinical development as one of the first topically administered proteins for the treatment of inflammatory diseases at the surface of the eye.
November 26, 2014
November 25, 2014
Events & Presentations
December 11, 2014 at 10:55 AM ET
November 13, 2014 at 8:30 AM ET